Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Omnicell Inc. (OMCL:NASDAQ), powered by AI.
Omnicell Inc. is currently trading at $39.90. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Omnicell Inc. on Alpha Lenz.
Omnicell Inc.'s P/E ratio is 893.8.
“Omnicell Inc. trades at a P/E of 893.8 (premium valuation) with modest ROE of 0.2%.”
Ask for details →Omnicell Inc. operates as a provider of medication management solutions and adherence tools within the healthcare industry. Its primary function is to optimize medication management and supply chain processes in healthcare facilities, aiming to enhance safety and efficiency. The company offers automated dispensing systems, pharmacy automation equipment, and software solutions tailored for acute care hospitals, long-term care settings, and other healthcare facilities. Notable features of Omnicell’s offerings include their ability to reduce medication errors, improve workflow efficiency, and facilitate better inventory management. Omnicell plays a significant role in the healthcare sector, impacting hospitals' and pharmacies' ability to comply with stringent regulatory standards while maintaining high levels of patient care. By integrating advanced technologies such as robotics, analytics, and cloud-based solutions, Omnicell supports the digital transformation of medication management, addressing challenges associated with manual processes and medication non-adherence. The company’s market significance is evident as it continually adapts to the evolving needs of healthcare providers, ensuring effective medication administration and promoting patient safety on a global scale.
“Omnicell Inc. trades at a P/E of 893.8 (premium valuation) with modest ROE of 0.2%.”
Ask for details →Omnicell Inc. (ticker: OMCL) is a company listed on NASDAQ in the Healthcare sector (Health Information Services). It has approximately 3,650 employees. Market cap is $1.8B.
The current price is $39.9 with a P/E ratio of 893.76x and P/B of 1.49x.
ROE is 0.17% and operating margin is 0.44%. Annual revenue is $1.2B.